Management of Hypertension and Anxiety

Introduction to Hypertension Management

The European Society of Cardiology recommends ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, and thiazide/thiazide-like diuretics as first-line medications for hypertension, due to their effective reduction in blood pressure and cardiovascular events 1
The American Heart Association and European Society of Cardiology suggest that beta-blockers should only be used for patients with specific compelling indications, such as angina, post-myocardial infarction, heart failure with reduced ejection fraction, or heart rate control 2, 1

The European Society of Cardiology notes that beta-blockers should not be used as first-line therapy for anxiety, as they lack robust evidence for treating anxiety disorders, and propranolol is only recommended for performance anxiety and symptomatic treatment when anxiety has prominent physical cardiovascular symptoms 2, 3
The International Society of Hypertension recommends addressing anxiety separately with appropriate psychiatric management, such as SSRIs, SNRIs, or cognitive behavioral therapy, and using RAS inhibitors and diuretics as preferred agents due to lower rates of pharmacological interactions 4, 5

The European Society of Cardiology gives a Class I recommendation for upfront combination therapy using two first-line agents, preferably as a single-pill combination, for confirmed hypertension, with options including RAS blocker + calcium channel blocker or RAS blocker + thiazide/thiazide-like diuretic 2, 1, 3

The European Society of Cardiology recommends monitoring heart rate carefully when using beta-blockers, with a target above 60-70 bpm, and never abruptly discontinuing beta-blockers to avoid rebound hypertension or symptom exacerbation 6, 7
The American Heart Association suggests screening for contraindications, such as asthma, severe bradycardia, heart block, or decompensated heart failure, when using beta-blockers 6, 7

The American Heart Association recommends avoiding propranolol in patients with second- or third-degree AV block, severe bradycardia, or sick sinus syndrome 8, 9
The American Heart Association also recommends avoiding propranolol in patients with decompensated heart failure or cardiogenic shock 8, 9
The American Heart Association advises against using propranolol in patients with reactive airway disease or severe asthma, though mild COPD may tolerate low-dose cardioselective agents 8, 10
The American Heart Association recommends avoiding propranolol in patients with severe hypotension (systolic BP <90 mmHg) 9, 10

The American College of Cardiology recommends exercising caution when combining propranolol with other AV nodal blocking agents or medications that prolong PR interval 8
The European Society of Cardiology advises against using propranolol as monotherapy for generalized anxiety disorder, as it is ineffective and delays appropriate psychiatric treatment 11